ABIVAX Société Anonyme (ABVX.PA)

EUR 7.48

(2.89%)

Market Cap (In EUR)

473.75 Million

Revenue (In EUR)

4.62 Million

Net Income (In EUR)

-147.74 Million

Avg. Volume

18.04 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.95-15.42
PE
-
EPS
-
Beta Value
1.423
ISIN
FR0012333284
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Marc M. P. de Garidel M.B.A.
Employee Count
-
Website
https://www.abivax.com
Ipo Date
2015-06-26
Details
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.